SCHEMBL4914946

SCHEMBL4914946

CC(C)CC(C)NCCNCCNCCNC(C)CC(C)C

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.34
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
SIGMAR1 Q99720 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742297 1.00 ALDH1A1 (0.34) ALDH1A1TSHRMAPK1SIGMAR1
SCHEMBL5040596 1.00 ALDH1A1 (0.34) ALDH1A1TSHRMAPK1SIGMAR1
SCHEMBL1241849 0.91 ALDH1A1 (0.38) ALDH1A1TSHRMAPK1SIGMAR1
SCHEMBL4915162 0.89 CA12 (0.48) ALDH1A1TSHR
SCHEMBL4915332 0.89 CA12 (0.48) ALDH1A1TSHR
SCHEMBL16314545 0.89 SLC6A4 (0.36) ALDH1A1TSHR
SCHEMBL4915009 0.89 CA12 (0.48) ALDH1A1TSHR
SCHEMBL31453491 0.87 LMNA (0.41)
SCHEMBL7113510 0.84 CYP2C19 (0.38) ALDH1A1TSHRSIGMAR1
SCHEMBL9453455 0.79 ALDH1A1 (0.31) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1914254-B1 Crosslinkers for improving stability of polyurethane foams EVONIK DEGUSSA GMBH (DE) 2017-08-23 EP claimed
US-8552078-B2 Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance AIR PRODUCTS AND CHEMICALS, INC. (US) 2013-10-08 US claimed
EP-1914254-A1 Crosslinkers for improving stability of polyurethane foams Air Products and Chemicals, Inc. (US) 2008-04-23 EP claimed
US-20080090922-A1 Crosslinkers for improving stability of polyurethane foams EVONIK OPERATIONS GMBH (DE) 2008-04-17 US claimed
EP-3390483-B1 ENCAPSULATION PROCTER & GAMBLE (US) 2022-05-18 EP disclosed
EP-3368207-B1 ENCAPSULATION ENCAPSYS LLC (US) 2021-12-01 EP disclosed
US-10864167-B2 Encapsulation THE PROCTER & GAMBLE COMPANY (US) 2020-12-15 US disclosed
EP-3390483-A1 ENCAPSULATION The Procter and Gamble Company (US) 2018-10-24 EP disclosed
EP-3368207-A1 ENCAPSULATION ENCAPSYS, LLC (US) 2018-09-05 EP disclosed
US-20180235893-A1 ENCAPSULATION THE PROCTER & GAMBLE COMPANY 2018-08-23 US disclosed
US-9937477-B2 Encapsulation WATERTITE PRODUCTS, INC. 2018-04-10 US disclosed
EP-1914254-B1 Crosslinkers for improving stability of polyurethane foams EVONIK DEGUSSA GMBH (DE) 2017-08-23 EP disclosed
WO-2017074997-A1 ENCAPSULATION ENCAPSYS, LLC (US) 2017-05-04 WO disclosed
WO-2017074995-A1 ENCAPSULATION ENCAPSYS, LLC (US) 2017-05-04 WO disclosed
US-20170113200-A1 Encapsulation Encapsys,LLC (US) 2017-04-27 US disclosed
US-8552078-B2 Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance AIR PRODUCTS AND CHEMICALS, INC. (US) 2013-10-08 US disclosed
EP-1914254-A1 Crosslinkers for improving stability of polyurethane foams Air Products and Chemicals, Inc. (US) 2008-04-23 EP disclosed
US-20080090922-A1 Crosslinkers for improving stability of polyurethane foams EVONIK OPERATIONS GMBH (DE) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180235893-A1 ENCAPSULATION ACR, ACMSD, SAMM50 ALDH1A1 592/4885TSHR 4720/4885MAPK1 2990/4885
US-10864167-B2 Encapsulation ACR, MPHOSPH6, ACMSD ALDH1A1 810/4885TSHR 4661/4885MAPK1 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.